Viscoelasticity Reprograms T Cell Metabolism for TCR-T Cell Manufacturing and Therapy

The cells that train cancer-fighting T cells work better when they squish back slowly rather than hold their shape, according to a UCLA–USC team whose study, “Viscoelasticity reprograms T cell metabolism for TCR-T cell manufacturing and therapy,” was published in Nature.

The researchers built synthetic viscoelastic activating cells — SynVACs — artificial antigen-presenting cells whose stress-relaxation speed can be chemically tuned while stiffness and the densities of peptide–MHC complexes and co-stimulatory ligands are held constant, according to the study abstract indexed at Duke’s scholar database.

Fast-relaxing versions of the particles amplified T cell receptor signaling and mTOR activity, drove mitochondrial remodeling, and pushed antigen-specific T cells into an energetically favorable metabolic state with enhanced stem-like properties, the abstract states. In mouse models of melanoma and ovarian cancer, TCR-T cells expanded on fast-relaxing SynVAC-pMHC showed superior persistence and durable antitumor activity.

The platform also outperformed monocyte-derived dendritic cells at enriching antigen-specific CD8+ T cells, the authors reported, positioning a fully synthetic, scalable approach against the current cell-based standard for expanding TCR-T cells.

“These results establish cell-mimetic viscoelasticity as a key biophysical cue governing T cell metabolism and differentiation, and provide a scalable, fully synthetic strategy to manufacture potent TCR-T cells for solid tumor therapy.”

Who is on the paper

The author list runs deep across Los Angeles institutions. Park, Lili Yang and Song Li. Yan-Ruide Li, Yichen Zhu, Xinyuan Shen, Yuning Chen, Enbo Zhu and Lili Yang are also affiliated with UCLA’s Department of Microbiology, Immunology & Molecular Genetics, while Hao Zhou, Bella Raykowski and Keyue Shen represent USC’s Alfred E. Mann Department of Biomedical Engineering, with Zhou also listed at USC's Eli & Edythe Broad CIRM Center for Regenerative Medicine and Stem Cell Research.

Dexter Lai and Junyoung O. Park are affiliated with UCLA chemical and biomolecular engineering, Yihui Cen and Jingyi Jessica Li with UCLA computational medicine, and Emily Z. Y. Miller, Xiling Shen and Zhaohui Wang with the Terasaki Institute for Biomedical Innovation in Woodland Hills, California.

Jun Shen of UCLA chemistry and biochemistry, Keyue Shen at USC’s Norris Comprehensive Cancer Center, and Jingyi Jessica Li, who is also affiliated with Fred Hutchinson Cancer Center’s biostatistics program in Seattle, round out the team.

Metabolic profiling in the paper’s extended data measured oxygen consumption rate and extracellular acidification rate in ESO-T cells activated with SynVAC-pMHC for 48 hours, comparing fast-, medium- and slow-relaxing particles against an IL-2-only control, with intracellular lactate, TCA cycle metabolites, and FLIM-based measurements of cell size, redox ratio and mitochondria size analyzed across donor samples, according to the paper’s figure legends.

Inside the metabolic assays

The extended-data figure legends give more detail on how those measurements were made. Oxygen consumption and extracellular acidification were tracked over time in ESO-T cells from two different donors, with sequential addition of Oligomycin, FCCP, and Rotenone/Antimycin A, and normalized basal and maximal values quantified for both readouts. Intracellular metabolites were quantified by pathway — TCA cycle, cofactors and nucleotides — alongside lactate, with composite scores calculated by averaging normalized values.

Fluorescence-lifetime imaging results were compared across groups for cell size, circularity and the α-bound and t-bound parameters, and UMAP plots visualized the four groups with overlaid single-cell characteristics including NAD(P)H intensity, redox ratio, mitochondria size and mitochondria size normalized to cell size, with an arrow marking the spread-cell population.

Significance in these analyses was determined by one-way ANOVA, and histograms of cell diameters in micrometers were plotted for cells activated by the fast-, medium- and slow-relaxing particles.

The study is a follow-up to the group’s earlier work on SynVACs: a 2024-2025 paper in Nature Biomedical Engineering described a high-throughput microfluidic system for fabricating the viscoelastic cells, which expanded human CD8+ T cells more substantially than rigid or elastic microspheres, suppressed regulatory T cell formation, achieved roughly 90% CAR-transduction efficiency, and produced CAR T cells that eliminated tumor cells in a human lymphoma mouse model and suppressed growth in ovarian cancer xenografts, per that paper’s PubMed record.

That record also notes the earlier SynVAC work reported substantial increases in T memory stem cells, longer persistence and reduced tumor-recurrence risk. UCLA bioengineers Youcheng Yang, Yan-Ruide Li and Zeyang Liu contributed equally to the new Nature study, which also lists co-senior authors Song Li and Lili Yang of UCLA and Keyue Shen of USC among a large multi-institution team spanning the Terasaki Institute and Fred Hutchinson Cancer Center.

The PubMed record for the earlier paper lists a competing-interest disclosure: Zeyang Liu, Yan-Ruide Li, Lili Yang and Song Li filed a patent application, PCT/US24/22516, on SynVAC as inventors, while the other authors declared no competing interests.

The Nature paper establishes viscoelasticity — how quickly a synthetic cell relaxes mechanical stress — as a tunable manufacturing parameter for T cell therapy, not merely a byproduct of材料 design.

Photo of author

Technology Desk

Technology Desk at Archyde.

I Lost My Adventurer’s License Anime Reveals Jan. 7 Premiere, Opening Theme in New Trailer